Results 41 to 50 of about 13,459 (185)

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report

Frontiers in Oncology, 2018
Melanoma is considered an aggressive malignancy with a tendency of forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location.
Guna Proboka, Andra Tilgase, Sergejs Isajevs, Sergejs Isajevs, Agnija Rasa, Pēteris Alberts   +5 more
doaj   +1 more source

Current strategies in engaging oncolytic viruses with antitumor immunity

Molecular Therapy: Oncolytics, 2021
Oncolytic virotherapy has produced promising yet limited results in preclinical and clinical studies. Besides direct oncolytic activity, a significant therapeutic mechanism of oncolytic virotherapy is the induction of tumor-specific immunity ...
Drew Ashton Boagni, Divya Ravirala, Shaun Xiaoliu Zhang   +2 more
doaj   +1 more source

Exploiting tumor epigenetics to improve oncolytic virotherapy [PDF]

, 2013
Oncolytic viruses (OVs) comprise a versatile and multi-mechanistic therapeutic platform in the growing arsenal of anticancer biologics. These replicating therapeutics find favorable conditions in the tumor niche, characterized among others by increased ...
Hesham Abdelbary, Jean-Simon Diallo, John C. Bell, Mathieu Lupien, Nicole E. Forbes   +4 more
core   +1 more source

Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction. [PDF]

, 2017
LuIII, a protoparvovirus pathogenic to rodents, replicates in human mitotic cells, making it applicable for use to kill cancer cells. This virus group includes H-1 parvovirus (H-1PV) and minute virus of mice (MVM).
Agbandje-McKenna, Mavis, Baker, Timothy S, Chipman, Paul, Cotmore, Susan, D'Abramo, Anthony, Geilen, Lorena, Halder, Sujata, Janssen, Mandy, Kurian, Justin, Mckenna, Robert, Misseldine, Adam, Pittman, Nikéa, Smith, J Kennon, Tattersall, Peter   +13 more
core   +3 more sources

Personalized virotherapy in cancer

Aging, 2015
After decades of intensive research, pancreatic adenocarcinoma (PDAC) remains a highly lethal disease with a median survival time that does not exceed 6.5 months [1]. Since more than 80% of patients present with advanced metastatic disease, systemic chemotherapy remains the only treatment.
Cafferata Eduardo G, Podhajcer, Osvaldo Luis   +1 more
openaire   +3 more sources

Cytokines in oncolytic virotherapy

Cytokine & Growth Factor Reviews, 2020
Tumors represent a hostile environment for the effector cells of cancer immunosurveillance. Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly exposed and released by malignant entities and their stromal accomplices. As a consequence, executioners of antitumor immunity inefficiently navigate across cancer tissues and fail ...
Pol, Jonathan, Workenhe, Samuel, Konda, Prathyusha, Gujar, Shashi, Kroemer, Guido   +4 more
openaire   +3 more sources

Experimental Evolution of an Oncolytic Vesicular Stomatitis Virus with Increased Selectivity for p53-Deficient Cells [PDF]

, 2014
Experimental evolution has been used for various biotechnological applications including protein and microbial cell engineering, but less commonly in the field of oncolytic virotherapy.
A Buckling, A Takaoka, AT Da Poian, BD Lichty, BK Jha, BW Grinnell, C Muñoz-Fontela, Carmen Rivas, DF Stojdl, E Hastie, EJ Faul, F Le Boeuf, G Wollmann, G Wollmann, GJ Letchworth, I Kuhn, I Pagán, I Palmero, IP Greene, IS Novella, J Martínez-Picado, JD Walker, Jean-Simon Diallo, JF Heiber, JJ Bull, JM Cuevas, JM Cuevas, JS Diallo, K Rainwater-Lovett, L Marcos-Villar, L Wu, M Dragosits, Marta M. Alonso, MG Kurilla, O Ebert, P Agudelo-Romero, Pablo Hernández-Alonso, PE Turner, R Alemany, R Belshaw, R Miralles, R Sanjuán, R Sanjuán, RA Burrell, Rafael Sanjuán, Raquel Garijo, RD Socha, S Elena, S Roche, SF Elena, SJ Russell, SK Remold, SP Whelan, TG Uil, TS Miest, V Furió, V Janelle, W Yan, Y Gao, Z Zhang   +59 more
core   +5 more sources

Oncolytic virotherapy for ovarian cancer [PDF]

Oncolytic Virotherapy, 2012
In the past two decades, more than 20 viruses with selective tropism for tumor cells have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of these viruses, eleven have been tested in human ovarian cancer models in preclinical studies.
Li, Shoudong, Tong, Jessica, Rahman, Masmudur M., Shepherd, Trevor G., McFadden, Grant   +4 more
openaire   +4 more sources

Tumor treatment with chemo-virotherapy and MEK inhibitor: A mathematical model of Caputo fractional differential operator

Alexandria Engineering Journal, 2023
Mitogen-activated protein kinase (MEK) inhibitors and oncolytic virotherapy are identified as promising cancer therapies that can enhance the efficacy of other cancer treatments.
M. Moksud Alam, S.M.E.K. Chowdhury, J.T. Chowdhury, Mohammad Mahmud Hasan, M.A. Ullah, Shams Forruque Ahmed   +5 more
doaj   +1 more source

Retargeted adenoviruses for radiation-guided gene delivery [PDF]

, 2016
The combination of radiation with radiosensitizing gene delivery or oncolytic viruses promises to provide an advantage that could improve the therapeutic results for glioblastoma. X-rays can induce significant molecular changes in cancer cells.
A Beetz, AP Patel, BL Davidson, C Roller, Cancer Genome Atlas Research Network, D E Hallahan, DA Boothman, DA Reardon, DA Spencer, DE Hallahan, DY Dadey, F Tameire, G Bajocchi, H Hsu, H Li, H Yan, HO McCarthy, JJ Mezhir, K Daino, L N Kaliberova, LM Hendershot, M Gonzalez-Gronow, M Hamdi, M Martin, M Westphal, MA Arap, MJ Gray, N Belousova, N Mittereder, R Datta, R Stupp, R Stupp, RJ Passarella, RR Weichselbaum, S A Kaliberov, S Akli, S Mittal, S Parisi, S Takahashi, SA Kaliberov, SC Noureddini, SL Eck, SS Talibi, T Ichikawa, TA Ajith, TC He, Ulasov IV, V Kapoor, VN Krasnykh, WL Blalock, WW Zhang, X Xing, Y Touchefeu, Y Zhang, YL Tsai   +54 more
core   +2 more sources